**Supplementary Table 10. Comparison in characteristics and clinical outcomes of the patients according to the enrollment periods.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **~2011** **(n = 192)** | **2012~** **(n = 69)** |  ***p* value** |
| Baseline characteristics |  |  |  |
| Age, years | 56 (53–62) | 57 (48–66) | 0.10 |
| Male | 148 (77.1) | 49 (71.0) | 0.40 |
| Past SBP | 26 (13.5) | 16 (23.2) | 0.09 |
| Nosocomial | 30 (15.6) | 18 (26.1) | 0.08 |
| Shock | 5 (2.6) | 3 (4.3) | 0.75 |
| Hb | 10.6 ± 2.0 | 10.8 ± 2.2 | 0.46 |
| PLT | 75 (48–106) | 94 (51–141) | 0.33 |
| WBC | 6.94 (4.90–10.57) | 6.80 (5.20–10.43) | 0.63 |
| CRP | 21.6 (5.8–52.8) | 6.1 (1.9–18.5) | <0.001 |
| INR | 1.58 (1.37–1.88) | 1.56 (1.36–2.04) | 0.62 |
| Bilirubin | 4.27 (2.71–7.80) | 5.18 (2.70–9.78) | 0.27 |
| Albumin | 2.6 (2.2–2.9) | 2.6 (2.3–2.9) | 0.83 |
| Cr | 1.1 (0.8–1.6) | 1.0 (0.8–1.4) | 0.06 |
| Child-Pugh score | 10 (9–12) | 11 (9–12) | 0.39 |
| MELD | 20 (15–25) | 19 (17–24) | 0.94 |
| Ascites WBC | 2560 (965–6550) | 3000 (1290–6880) | 0.39 |
| Ascites PMN | 2094 (700–5329) | 2301 (847–5824) | 0.54 |
| Cultured bacteria | 57 | 25 | 0.27 |
| Escherichia Coli | 15 (26.3) | 13 (52.0) |  |
| Klebsiella | 16 (28.1) | 8 (32.0) |  |
| Streptococcus | 15 (26.3) | 2 (8.0) |  |
| Staphylococcus | 3 (5.3) | 0 |  |
| Aeromonas | 3 (5.3) | 2 (8.0) |  |
| Acinetobacter | 2 (3.5) | 0 |  |
| Bacteroides | 1 (1.8) | 0 |  |
| Bacillus | 1 (1.8) | 0 |  |
| Enterococcus | 1 (1.8) | 0 |  |
| Multi-drug resistance |   |   |  |
| MDR | 8 (14.0) | 8 (32.0) | 0.11 |
| XDR | 1 (1.8) | 0 | 0.99 |
| Treatment outcomes |  |  |  |
| rPMN>25% at 48h | 149 (77.6) | 53 (76.8) | 0.99 |
| ITT120cure | 140 (72.9) | 50 (72.5) | 0.99 |
| ITT168cure | 154 (80.2) | 57 (82.6) | 0.80 |
| Death in 1 month | 38 (19.8) | 10 (14.5) | 0.43 |
|  |  |  |  |

MDR (multidrug resistant bacteria), was defined as acquired non-susceptibility to at least one agent in 3 or more antimicrobial categories; XDR (Extensively-drug resistant bacteria) was defined as non-susceptibility to at least one agent in all but 2 or fewer antimicrobial categories and pandrug-resistant (PDR) as non-susceptibility to all currently available agents

Abbreviation: SBP, spontaneous bacterial peritonitis; CRP, C-reactive protein; Hb, hemoglobin; INR, international normalized ratio; Cr, creatinine; MELD, model for end stage liver disease; rPMN, reduction of polymorphonucleated cells; ITT120cure, resolution of spontaneous bacterial peritonitis assessed by intention-to-treat analysis at 120 hours; ITT168cure, resolution of spontaneous bacterial peritonitis assessed by intention-to-treat analysis at 168 hours;